Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration ...

The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

Scientists at St. Jude Children’s Research Hospital have designed new drug frameworks that selectively target CYP3A4, one of the most critical CYP proteins. Structural insights from this work offer a ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...